Elucidating the Nexus of Mitochondrial Dysfunction and Oncometabolite Accumulation in Tumorigenesis

Cancer is a complex disease driven by disruptions in cellular metabolism and mitochondrial function, enabling malignant cells to proliferate unchecked, evade apoptosis, and metastasize to distant organs. This exhaustive review elucidates the metabolic dysregulations inherent to cancer, with a particular focus on mitochondrial dysfunction, the accumulation of oncometabolites, and the reprogramming of metabolic pathways. A comprehensive literature search was conducted across major scientific databases, including PubMed, Web of Science, Scopus, and ScienceDirect, spanning January 2010 to March 2025. Controlled vocabulary and Boolean operators were employed to capture relevant studies, focusing on cancer metabolism, metabolic reprogramming, tumour markers, oncometabolites, mitochondrial dysfunction, and regulatory pathways. Extracted data were organized into thematic areas, and a qualitative synthesis approach was used to integrate findings, identifying common mechanistic patterns underlying tumour initiation, progression, and metastasis. The Warburg effect, a typical feature of cancer metabolism, is characterized by a predilection for aerobic glycolysis, thereby supporting biosynthetic processes and contributing to tumour microenvironment acidification and immune suppression. Mitochondrial dysfunction triggers genomic instability and oncogenic transformation. Meanwhile, oncometabolites like 2-hydroxyglutarate, fumarate, and sarcosine disrupt cellular signalling and epigenetic regulation, promoting tumour growth and progression. The clinical significance of tumour markers and metabolic biomarkers is underscored, and the systemic metabolic sequelae of cancer, including cancer-associated cachexia, are expounded upon. In glioblastoma, Aurora kinase A inhibition reverses the Warburg effect, decreasing glucose uptake and boosting oxidative phosphorylation. Cancer-associated fibroblasts exhibit aerobic glycolysis, promoting tumor growth and metastasis via the reverse Warburg effect. Glycolysis inhibition suppresses tumor growth in pancreatic cancer, and the Warburg effect contributes to chemoresistance by upregulating glycolytic enzymes and increasing lactate production. Targeting the Warburg effect, including inhibiting glycolytic enzymes and modulating mitochondrial function, offers potential therapeutic strategies for cancer treatment. This review provides a comprehensive exposition of the biochemical mechanisms underpinning metabolic derangements in cancer, which may unveil novel avenues for diagnostic and therapeutic interventions.